news

Spartan’s COVID-19 test recall exposes issues of rapid medical device approval, says report

16
SHARES

Following the recall of Spartan Bioscience’s COVID-19 test by Health Canada, a report suggests this demonstrates the challenges associated with rapid approval.

COVID-19 test

Following the announcement that Spartan Bioscience has recalled its rapid COVID-19 test due to concerns by Health Canada, a new report has highlighted the challenges presented by rapid medical device approval. 

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

Dr Azadeh Laffafian, Medical Device Analyst at GlobalData, said: “Recall of Saprtan’s COVID-19 test is not surprising as extraordinary circumstances have accelerated the approval of medical devices. While fast tracking of medical products needed to address COVID-19 is important, it is also imperative that proper screening and quality assurance take place.

Spartan’s test kit was approved by Health Canada in April in an expedited fashion. However, in early May, the test was recalled due to concerns regarding efficacy of its proprietary swab, raised by Health Canada. Spartan is currently working on addressing concerns and is hoping to quickly bring the product to market.

“If Spartan is able to quickly address current concerns and no other issues arise, it is likely that the test kit will be highly utilised in Canada. Canadian provinces are hoping to continue to increase testing and new qualified tests are welcomed. Additionally, the kit’s portable and rapid nature makes it an attractive product. The test can be performed in settings such as airports and doctor’s offices by non-laboratory personnel. This is especially helpful for rural and remote areas where access to testing laboratories is limited.

“If Spartan’s tests are successful in Canada and the company is able to ramp up enough production, it is likely that the kit will also be exported, as the company had previously indicated a global interest in its product.”

Related people

Related diseases & conditions

,

Leave a Reply

Your email address will not be published. Required fields are marked *

Share via
Share via